Skip to content
FIND A HEALTH VALLEY ACTOR

CSEM develops a pioneering implant to support reproductive medicine

Swiss-based start-ups Impli and Yalosys, along with the technology innovation centre CSEM, announce a significant milestone in women’s healthcare—CERES. This implantable biosensor for real-time fertility hormone monitoring is now set to undergo a transformation that will make it ready for human trials by 2025.     With Impli’s expertise, the biosensor has matured from a…

Read More

UNIGE and UNIFR collaborate in breakthrough cell membranes research

UNIGE-cell-membrane

UNIGE scientists have discovered how yeast cells sense physical stresses on the membranes that protect them.     Cell membranes play a crucial role in maintaining the integrity and functionality of cells. However, the mechanisms by which they perform these roles are not yet fully understood. Scientists from the University of Geneva (UNIGE), in collaboration…

Read More

Regenosca closes CHF 1Million pre-seed round

Regenosca closes CHF 1Million pre-seed round to demonstrate endoscopic delivery of TissueSpan implants.     Regenosca creates unique bio-implants, enabling the body to attract and organise its own cells for seamless healing. Providing a temporary, naturally absorbed bridge, the TissueSpan technology replaces diseased tissue and restores patients to full health. With access to markets worth…

Read More

Swiss Venture Capital Report: CHF 1.1 Billion for Swiss startups

Swiss venture capital financing remained at the low level of the previous year in the first half of 2024, with CHF 1’082.4 Million going to 138 financing rounds. Nevertheless, there were also positive signs, such as an increase in investment in the biotech sector.     This half-year update to Swiss Venture Capital Report, published…

Read More

Agora Care raised CHF 2.2 Million

Agora care-round closing

Agora Care, a Campus Biotech-based startup, announced the closing of its round of financing of CHF 2.2 Million     This capital increase will help launching a promotional campaign and strategic partnerships in the US market. Furthermore, it will also enable the expansion of patient enrolment in Switzerland and Europe through a new process that…

Read More

Asceneuron secures $100 Million Series C

Asceneuron-seriesc

Asceneuron secures $100 Million Series C financing to advance groundbreaking therapeutics in neurodegenerative diseases.     Asceneuron SA, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, announced a $100 Million oversubscribed Series C financing to advance the clinical development of its groundbreaking clinical pipeline of…

Read More

Csky.ai Seed closed CHF 1 Million seed round

Csky.ai

Swiss Edge AI startup csky.ai has just closed its seed round, exceeding CHF 1 Million of total funding inclusive of equity, grants, and loans raised since the company launch. Among the investors are several Swiss, French and American business angels, the Founderful Fund and two companies. The raised funds are set to take the startup…

Read More

Aspivix among the 15th French American Entrepreneurship Award winners

aspivix Faea

The French American Entrepreneurship Award (FAEA) has concluded its 15th year by recognizing three exceptional early-stage startups led by French entrepreneurs in the US.     Since 2008, the FAEA has supported innovation and growth for these businesses, helping them succeed in the American market. A Jury, comprised of a Panel of Experts and FAEA…

Read More

CEIDOS secures support from Innosuisse

CEIDOS-news

The BioArk-based startup announced that its innovation project has been approved by the Innosuisse Innovation Council, securing significant funding.     With a total of CHF 1.2 Million, CEIDOS will elevate its C-Netics technology in partnership with CSEM and HES-SO Valais-Wallis. This project will enhance the startup on-line monitoring technology, enabling continuous and more precise control…

Read More

HAYA Therapeutics co-founders win inaugural Andreas & Thomas Struengmann Award

Haya therapeutics AT awards

HAYA Therapeutics, SA, announced that HAYA’s Co-Founders Samir Ounzain and Daniel Blessing have received the inaugural Andreas & Thomas Struengmann Award.     Recognising entrepreneurial vision and talent in the life sciences among the DACH region, which includes Germany, Austria and Switzerland, the award honours the efforts of Drs. Ounzain and Blessing in creating a…

Read More